Boston Scientific (BSX) Depreciation & Amortization (CF) (2020 - 2026)

Boston Scientific has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $351.0 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $351.0 million, up 8.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 8.06% YoY), and the FY2025 annual result was $1.4 billion, up 7.8% from the prior year.
• Depreciation & Amortization (CF) came in at $351.0 million for Q1 2026 at Boston Scientific, down from $365.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $365.0 million in Q4 2025 to a low of $274.0 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $306.0 million (2024), against an average of $312.9 million.
• Across the five-year window, Depreciation & Amortization (CF) increased 1.38% in 2022 and climbed 11.76% in 2025, its largest moves.
• Boston Scientific's Depreciation & Amortization (CF) stood at $294.0 million in 2022, then advanced by 6.46% to $313.0 million in 2023, then increased by 11.18% to $348.0 million in 2024, then grew by 4.89% to $365.0 million in 2025, then slipped by 3.84% to $351.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $351.0 million (Q1 2026), $365.0 million (Q4 2025), and $342.0 million (Q3 2025), per Business Quant data.